{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:58:53Z","timestamp":1776470333665,"version":"3.51.2"},"reference-count":43,"publisher":"Universa BV","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>The association between dipeptidyl peptidase-4 (DPP-4) inhibitors, known as gliptins, and acute pancreatitis raises growing concern. A systematic search of PubMed, Scopus and Web of Science was conducted for studies published between January 2005 and July 2024. Studies focusing on gliptin-induced pancreatitis were selected based on predefined criteria. While gliptins are effective in managing type 2 diabetes mellitus, several case reports and observational studies suggest a potential risk for inducing acute pancreatitis. Proposed mechanisms include increased pancreatic activity and cellular stress. Clinical presentation often includes abdominal pain and elevated pancreatic enzymes, necessitating prompt diagnosis and discontinuation of the offending agent. Early recognition and management, including discontinuation of the drug and supportive care, are crucial. Balancing benefits and risks of gliptin therapy is essential for ensuring patient safety and optimal outcomes. This review underscores the importance of vigilance among healthcare providers and the need for further research to develop safer therapeutic strategies.<\/jats:p>","DOI":"10.51821\/88.1.13722","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T17:23:54Z","timestamp":1751217834000},"page":"151","source":"Crossref","is-referenced-by-count":2,"title":["Gliptin induced acute pancreatitis: a literature review"],"prefix":"10.51821","volume":"88","author":[{"given":"G","family":"Jaya Pragadeesh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheik Asik","family":"Abu Sali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Rajesh Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanashri","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Dheepthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref0","unstructured":"COLUMBIA SURGERY, 2024, The pancreas and its functions, Columbiasurgery.org, viewed 8 July 2024, <https:\/\/www.columbiasurgery.org\/>."},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"BHATIA M., WONG F.L., CAO Y., LAU H.Y., HUANG J., PUNEET P., et al. Pathophysiology of acute pancreatitis. Pancreatology, 2005, 5: 132\u201314.","DOI":"10.1159\/000085265"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"IANNUZZI J.P., KING J.A., LEONG J.H., QUAN J., WINDSOR J.W., TANYINGOH D., et al. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis. Gastroenterology, 2022, 162(1): 122\u201334.","DOI":"10.1053\/j.gastro.2021.09.043"},{"key":"ref3","unstructured":"WORLD HEALTH ORGANIZATION, 2020, Diabetes. World Health Organization, viewed 15 July 2024, <https:\/\/www.who.int\/news-room\/ fact-sheets\/detail\/diabetes\/>."},{"key":"ref4","unstructured":"UPTODATE, 2024, Type 2 diabetes mellitus: Prevalence and risk factors. UpToDate, viewed 10 July 2024, <https:\/\/www.uptodate.com\/contents\/ type-2-diabetes-mellitus-prevalence-and-risk-factors\/>."},{"key":"ref5","unstructured":"DIABETES UK, 2017, DPP-4 inhibitors (gliptins). Diabetes UK, viewed 3 July 2024, <https:\/\/www.diabetes.org.uk\/>."},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"SUN Z.G., LI Z.N., ZHU H.L. The research progress of DPP-4 inhibitors. Mini Rev Med Chem., 2020, 20(17): 1709-1718.","DOI":"10.2174\/1389557520666200628032507"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"BOHANNON N. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice. Postgrad Med., 2009, 121(1): 40\u20135.","DOI":"10.3810\/pgm.2009.01.1953"},{"key":"ref8","unstructured":"SEERY C, 2019, DPP-4 inhibitors (gliptins). Diabetes, viewed 21 July 2024, <https:\/\/www.diabetes.org.uk\/>."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"JAYARAMAN M., KUMAR S., SOOD A. Acute pancreatitis with gliptins: Is it a clinical reality?. Indian J Endocrinol Metab., 2013, 17(7): 323.","DOI":"10.4103\/2230-8210.119644"},{"key":"ref10","unstructured":"JONES M.R., HALL O.M., KAYE A.M., KAYE A.D. Drug-induced acute pancreatitis: A review. Ochsner J., 2015 Spring, 15(1): 45\u201351."},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"SCHEEN A.J. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf., 2015 Feb, 14(2): 287-300.","DOI":"10.1517\/14740338.2015.1006625"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"ENGEL S.S., ROUND E., GOLM G.T., KAUFMAN K.D., GOLDSTEIN B.J., AGRAWAL R. Safety and tolerability of sitagliptin in type 2 diabetes: Pooled analysis of 25 clinical studies. Diabetes Ther, 2013, 4(1): 119-145.","DOI":"10.1007\/s13300-013-0024-0"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"AMORI R.E., LAU J., PITTAS A.G., et al. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA, 2007, 298(2): 194-206.","DOI":"10.1001\/jama.298.2.194"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"ELASHOFF M., MATVEYENKO A.V., GIER B., ELASHOFF R., BUTLER P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon- like peptide-1\u2013based therapies. Gastroenterology, 2011, 141(1): 150\u20136.","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"ref15","unstructured":"U.S. FOOD AND DRUG ADMINISTRATION (FDA), 2025, FDA Drug Safety Communication: FDA warns DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. FDA.gov, viewed 19 February 2025, <https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause- severe-joint-pain\/>."},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"HERMANSEN K., KIPNES M., LUO E., FANURIK D., KHATAMI H., STEIN P.P., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diab. Obes. Metab., 2007, 9(5): 733-745.","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"SCIRICA B.M., BHATT D.L., BRAUNWALD E., STEG P.G., DAVIDSON J., HIRSHBERG B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med., 2013, 369(14): 1317-1326.","DOI":"10.1056\/NEJMoa1307684"},{"key":"ref18","unstructured":"AHREN B., FOLEY J.E., BOSI E. Clinical evidence and mechanistic basis for vildagliptin\u2019s effect in combination with metformin or pioglitazone. J. Diabetes Complications., 2011, 25(5): 363-371."},{"key":"ref19","unstructured":"WANG T., SHANKAR S.S. Dipeptidyl peptidase-4 inhibitors and pancreatitis: A nationwide case-control study in the US. Diabetes Care, 2015, 38(7): 1388-1394."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"ALOMAR M., TAWFIQ A.M., HASSAN N., PALAIAN S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: Current status, challenges and the future. Ther Adv Drug Saf., 2020, 11: 204209862093859.","DOI":"10.1177\/2042098620938595"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"PETROV M.S., YADAV D. Global epidemiology and holistic prevention of pancreatitis. Nat Rev Gastroenterol Hepatol., 2019, 16(3): 175\u201384.","DOI":"10.1038\/s41575-018-0087-5"},{"key":"ref22","unstructured":"FOURNIER C., NADERI S., AICHINGER G., DE KEYSER C. Riskfactors for pancreatitis in type 2 diabetes: A population-based cohort study. Diabetes Res. Clin. Pract.,2016, 115: 150-157."},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"SHIN K.Y., LEE W.S., CHUNG D.W., HEO J., JUNG M.K., TAK W.Y., et al. Influence of obesity on the severity and clinical outcome of acute pancreatitis. Gut Liver, 2011, 5(3): 335\u20139.","DOI":"10.5009\/gnl.2011.5.3.335"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"MONAMI M., DICEMBRINI I., MANNUCCI E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: A meta-analysis of randomized clinical trials. Diab. Obes. Metab., 2011, 13(1): 57-64.","DOI":"10.1185\/03007995.2011.602964"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"SINGH S., CHANG H.Y., RICHARDS T.M., WEINER J.P., CLARK J.M.,et al. Glucagon-like peptide 1\u2013based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Intern. Med., 2013, 173(7): 534-539.","DOI":"10.1001\/jamainternmed.2013.2720"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"BONFRATE L., WANG D.Q-H., GARRUTI G., PORTINCASA P. Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract Res Clin Gastroenterol., 2014, 28(4): 623\u201335.","DOI":"10.1016\/j.bpg.2014.07.013"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"LANKISCH P.G., APTE M., BANKS P.A. Acute pancreatitis. Lancet, 2015, 386(9988): 85\u201396.","DOI":"10.1016\/S0140-6736(14)60649-8"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"WOLFE D., KANJI S., YAZDI F., BARBEAU P., RICE D., BECK A., et al. Drug-induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLoS One, 2020, 15(4): e0231883.","DOI":"10.1371\/journal.pone.0231883"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"EL-ABHAR H.S., SCHAALAN M.F. Phytotherapy in diabetes: Review on potential mechanistic perspectives. World J Diabetes., 2014, 5(2): 176.","DOI":"10.4239\/wjd.v5.i2.176"},{"key":"ref30","unstructured":"AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS. Mechanism of vildagliptin action. Am J Health-Syst Pharm., 2007."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"BUTLER A.E., CAMPBELL-THOMPSON M., GURLO T., DAWSON T.L., et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine ductal proliferation. Diabetes, 2013, 62(7): 2595-2604.","DOI":"10.2337\/db12-1686"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"LIPPI G., VALENTINO M., CERVELLIN G. Laboratory diagnosis of acute pancreatitis: In search of the Holy Grail. Crit. Rev. Clin. Lab. Sci., 2012, 49(1): 18-31.","DOI":"10.3109\/10408363.2012.658354"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"BASNAYAKE C., RATNAM D. Abnormal laboratory results: Blood testsfor acute pancreatitis. Aust Prescr., 2015, 38(4): 128\u201330.","DOI":"10.18773\/austprescr.2015.043"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"MUNGAN Z., ATTILA T., UNAL KABAOGLU Z., VURAL M. Vildagliptin-induced acute pancreatitis without enzyme elevation. Turk J Gastroenterol., 2017, 28(6): 514\u20137.","DOI":"10.5152\/tjg.2017.17308"},{"key":"ref35","unstructured":"CLEVELAND CLINIC, 2025, Gallstone pancreatitis. Cleveland Clinic,viewed 27 January 2025, <https:\/\/my.clevelandclinic.org\/>."},{"key":"ref36","unstructured":"MEDSCAPE, 2023, Acute pancreatitis imaging. Medscape.com, viewed 27 January 2025, <https:\/\/www.medscape.com\/>."},{"key":"ref37","unstructured":"KARSENTI D., TOCI R., KARSENTI D., GRIMALDI D. Acute pancreatitis due to vildagliptin: A case report. BMC Pharmacol Toxicol., 2014, 15: 38."},{"key":"ref38","unstructured":"EUROPEAN MEDICINES AGENCY (EMA), 2020, Assessment report: Incretin-based therapies. EMA, viewed July 2024, <https:\/\/www.ema.europa.eu\/en\/>."},{"key":"ref39","unstructured":"BERGMAN A.J., STEVENS C., ZHOU Y., YI B. Pharmacokinetic and pharmacodynamic properties of DPP-4 inhibitors: Impact of differences in structure and formulation. Adv Drug Deliv Rev., 2011, 63(7): 539-552."},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"TK\u00c1\u010c I., RAZ I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care, 2017, 40(2): 284-286.","DOI":"10.2337\/dc15-1707"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"BUTLER A.E., CAMPBELL-THOMPSON M., GURLO T., et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine ductal proliferation. Diabetes, 2013, 62(7): 2595-2604.","DOI":"10.2337\/db12-1686"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"NAUCK M.A., MEININGER G., SHENG D., TERRANELLA L., STEIN P.P., SITAGLIPTIN STUDY 024 GROUP. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diab. Obes. Metab., 2007, 9(2): 19","DOI":"10.1111\/j.1463-1326.2006.00704.x"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"deposited":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T17:44:40Z","timestamp":1751219080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2237\/Gliptin%20induced%20acute%20pancreatitis:%20a%20literature%20review\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.51821\/88.1.13722","relation":{},"ISSN":["1784-3227","1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"},{"value":"1784-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}